ACR 2022 Tweet by Mike Putman

Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS

Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain)

Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited

#ACR22 @RheumNow abstr#1113